NeoGenomics Net Worth
NeoGenomics Net Worth Breakdown | NEO |
NeoGenomics Net Worth Analysis
NeoGenomics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including NeoGenomics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of NeoGenomics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform NeoGenomics' net worth analysis. One common approach is to calculate NeoGenomics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares NeoGenomics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing NeoGenomics' net worth. This approach calculates the present value of NeoGenomics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of NeoGenomics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate NeoGenomics' net worth. This involves comparing NeoGenomics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into NeoGenomics' net worth relative to its peers.
To determine if NeoGenomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeoGenomics' net worth research are outlined below:
| NeoGenomics generated a negative expected return over the last 90 days | |
| NeoGenomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 297.88 M. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Segall Bryant Hamill LLC Boosts Holdings in NeoGenomics, Inc. |
NeoGenomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NeoGenomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NeoGenomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know NeoGenomics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NeoGenomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeoGenomics backward and forwards among themselves. NeoGenomics' institutional investor refers to the entity that pools money to purchase NeoGenomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | American Century Companies Inc | 2025-03-31 | 3.3 M | T. Rowe Price Investment Management,inc. | 2025-03-31 | 3.3 M | Geode Capital Management, Llc | 2025-03-31 | 3.1 M | Segall Bryant & Hamill | 2025-03-31 | 2.4 M | Loomis, Sayles & Company Lp | 2025-03-31 | 1.8 M | Goldman Sachs Group Inc | 2025-03-31 | 1.7 M | Northern Trust Corp | 2025-03-31 | 1.6 M | Fred Alger Management, Llc | 2025-03-31 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.5 M | Blackrock Inc | 2025-03-31 | 19.9 M | Vanguard Group Inc | 2025-03-31 | 14.3 M |
Follow NeoGenomics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 803.06 M.Market Cap |
|
Project NeoGenomics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.11) | |
| Return On Capital Employed | (0.07) | (0.07) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.08) |
When accessing NeoGenomics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures NeoGenomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeoGenomics' profitability and make more informed investment decisions.
Evaluate NeoGenomics' management efficiency
NeoGenomics has Return on Asset of (0.0275) % which means that on every $100 spent on assets, it lost $0.0275. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0857) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of July 2025, Return On Tangible Assets is likely to drop to -0.11. In addition to that, Return On Capital Employed is likely to grow to -0.07. At this time, NeoGenomics' Total Assets are very stable compared to the past year. As of the 20th of July 2025, Total Current Assets is likely to grow to about 625.8 M, while Other Assets are likely to drop about 3.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.12 | 7.48 | |
| Tangible Book Value Per Share | 0.31 | 0.29 | |
| Enterprise Value Over EBITDA | -1.5 K | -1.5 K | |
| Price Book Value Ratio | 0.46 | 0.44 | |
| Enterprise Value Multiple | (434.01) | (412.31) | |
| Price Fair Value | 0.46 | 0.44 | |
| Enterprise Value | 59.3 M | 52.7 M |
NeoGenomics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 1.5613 | Revenue | Quarterly Revenue Growth 0.075 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeoGenomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeoGenomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeoGenomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeoGenomics Corporate Filings
| 17th of July 2025 Other Reports | ViewVerify | |
8K | 24th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 16th of June 2025 Other Reports | ViewVerify | |
F4 | 3rd of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
NeoGenomics Earnings per Share Projection vs Actual
NeoGenomics Corporate Management
| Nathan MD | Vice Services | Profile | |
| George Cardoza | Pres Operations | Profile | |
| Gary Passman | Chief Officer | Profile | |
| Alicia Olivo | General Development | Profile | |
| Andrew Lukowiak | Chief Officer | Profile | |
| Cynthia Dieter | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 0.075 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.